FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely anaesthesiology and resuscitation, and concerns prevention of heart rhythm disorder in cardiac surgeries with the use of an cardiopulmonary bypass. That is ensured by the introduction of 25% magnesium sulphate 0.05-0.07 mmole/kg of patient's body weight before connection to the cardiopulmonary bypass and 0.05-0.07 mmole/kg before reperfusion through a special medicinal port.
EFFECT: dose schedule of the preparation enables cardiac stabilisation and prevented heart rhythm disorder during cardiac surgery.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MYOCARDIUM PROTECTION AGAINST REPERFUSION INJURIES IN HEART OPERATIONS (EMBODIMENTS) | 2019 |
|
RU2723509C1 |
| METHOD FOR CARDIOPLEGIC ARREST (VERSIONS) | 2015 |
|
RU2571058C1 |
| METHOD FOR RECONSTRUCTING CARDIAC ACTIVITY IN CASE OF OPERATIONS OF AORTOCORONARY BYPASS AT ARTIFICIAL CIRCULATION | 2006 |
|
RU2306138C1 |
| CARDIOPLEGIA AGENT (VERSIONS) | 2014 |
|
RU2568911C1 |
| METHOD OF PROPHYLAXIS OF HEART RHYTHM DISORDER IN CARDIOSURGERY OPERATIONS | 1997 |
|
RU2144362C1 |
| METHOD OF ERYTHROCYTES PROTECTION IN CARDIOSURGICAL PATIENTS OPERATED UNDER CONDITIONS OF ARTIFICIAL BLOOD CIRCULATION | 2019 |
|
RU2729026C1 |
| METHOD FOR PREVENTION OF CARDIAC RHYTHM DISTURBANCE IN CORONARY BYPASS | 2009 |
|
RU2392939C1 |
| METHOD OF CARRYING OUT CARDIOPLEGIA | 2009 |
|
RU2434589C2 |
| PROTECTIVE SOLUTION FOR PREVENTING OR REDUCING REPERFUSION INJURY OF BRAIN AND WHOLE BODY | 2014 |
|
RU2672558C2 |
| CRYSTALLOID CARDIOPLEGIC SOLUTION | 2009 |
|
RU2423135C2 |
